{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:46:24Z","timestamp":1792403184423,"version":"4.4.0"},"reference-count":148,"publisher":"Elsevier","isbn-type":[{"value":"9780128142554","type":"print"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008644","name":"Faculty of Medicine, McGill University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008644","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1016\/bs.pbr.2018.07.008","type":"book-chapter","created":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T22:08:55Z","timestamp":1535666935000},"page":"69-96","source":"Crossref","is-referenced-by-count":76,"title":["d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.pbr.2018.07.008_bb0010","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1146\/annurev-med-053013-062946","article-title":"Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics","volume":"66","author":"Abdallah","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0015","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1126\/science.161.3842.706","article-title":"Lysergic acid diethylamide: sensitive neuronal units in the midbrain raphe","volume":"161","author":"Aghajanian","year":"1968","journal-title":"Science"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0020","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1001\/archpsyc.57.3.270","article-title":"Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-d-aspartate receptor antagonists","volume":"57","author":"Anand","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0025","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0149-7634(82)90036-7","article-title":"Analyzing mechanism (s) of hallucinogenic drug action with drug discrimination procedures","volume":"6","author":"Appel","year":"1982","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0030","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00204-015-1513-x","article-title":"The hallucinogenic world of tryptamines: an updated review","volume":"89","author":"Ara\u00fajo","year":"2015","journal-title":"Arch. Toxicol."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0035","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0166-2236(96)10037-0","article-title":"Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists","volume":"19","author":"Artigas","year":"1996","journal-title":"Trends Neurosci."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0040","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1046\/j.1460-9568.1999.00708.x","article-title":"A pre-and postsynaptic modulatory action of 5-HT and the 5-HT2A, 2C receptor agonist DOB on NMDA-evoked responses in the rat medial prefrontal cortex","volume":"11","author":"Arvanov","year":"1999","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0045","series-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-5\u00ae)","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2018.02.018","article-title":"Psychedelics: where we are now, why we got here, what we must do","author":"Belouin","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0055","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1124\/mol.107.035170","article-title":"A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis","volume":"72","author":"Benneyworth","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0060","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0022-3999(01)00296-3","article-title":"The validity of the hospital anxiety and depression scale: an updated literature review","volume":"52","author":"Bjelland","year":"2002","journal-title":"J. Psychosom. Res."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0065","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0006-3223(02)01643-8","article-title":"Is there a role for 5-HT1A agonists in the treatment of depression?","volume":"53","author":"Blier","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0022-3565(25)38146-2","article-title":"Differential properties of pre-and postsynaptic 5-hydroxytryptamine1A receptors in the dorsal raphe and hippocampus: I. Effect of spiperone","volume":"265","author":"Blier","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0075","doi-asserted-by":"crossref","first-page":"8966","DOI":"10.1073\/pnas.151105198","article-title":"Trace amines: identification of a family of mammalian G protein-coupled receptors","volume":"98","author":"Borowsky","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0080","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/S0140-6736(02)08701-9","article-title":"Mescaline use for 5700 years","volume":"359","author":"Bruhn","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0085","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1124\/mol.60.6.1181","article-title":"Amphetamine, 3, 4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor","volume":"60","author":"Bunzow","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0090","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0026-895X(25)10799-2","article-title":"Binding interactions of lysergic acid diethylamide and related agents with dopamine receptors in the brain","volume":"12","author":"Burt","year":"1976","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0095","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00213-014-3658-3","article-title":"The role of 5-HT 2A, 5-HT 2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N, N-dimethyltryptamine and N, N-diisopropyltryptamine in rats and mice","volume":"232","author":"Carbonaro","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0100","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/schbul\/sbs117","article-title":"Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis","volume":"39","author":"Carhart-Harris","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0105","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fnhum.2014.00020","article-title":"The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs","volume":"8","author":"Carhart-Harris","year":"2014","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0110","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0115","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1017\/S0033291715002901","article-title":"The paradoxical psychological effects of lysergic acid diethylamide (LSD)","volume":"46","author":"Carhart-Harris","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0120","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1073\/pnas.1518377113","article-title":"Neural correlates of the LSD experience revealed by multimodal neuroimaging","volume":"113","author":"Carhart-Harris","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0125","doi-asserted-by":"crossref","first-page":"13187","DOI":"10.1038\/s41598-017-13282-7","article-title":"Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms","volume":"7","author":"Carhart-Harris","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0130","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0135","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.3390\/ijms17111953","article-title":"d-Lysergic acid diethylamide (LSD) as a model of psychosis: mechanism of action and pharmacology","volume":"17","author":"De Gregorio","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0140","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.phrs.2016.08.022","article-title":"The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors","volume":"113","author":"De Gregorio","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0145","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1001\/archinte.160.14.2101","article-title":"Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence","volume":"160","author":"Dimatteo","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0150","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1038\/npp.2016.82","article-title":"LSD acutely impairs fear recognition and enhances emotional empathy and sociality","volume":"41","author":"Dolder","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0155","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/2045125316638008","article-title":"Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years","volume":"6","author":"Dos Santos","year":"2016","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0160","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/2045125316689030","article-title":"Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies","volume":"7","author":"Dos Santos","year":"2017","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0165","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s002130050585","article-title":"Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors","volume":"136","author":"Egan","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0170","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1037\/0002-9432.77.4.534","article-title":"Prevalence and correlates of depression, anxiety, and suicidality among university students","volume":"77","author":"Eisenberg","year":"2007","journal-title":"Am. J. Orthopsychiatry"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0175","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.psychres.2013.02.007","article-title":"Apathy, poor verbal memory and male gender predict lower psychosocial functioning one year after the first treatment of psychosis","volume":"210","author":"Faerden","year":"2013","journal-title":"Psychiatry Res."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0180","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF02246074","article-title":"The role of the 5-HT 2A and 5-HT 2C receptors in the stimulus effects of hallucinogenic drugs I: antagonist correlation analysis","volume":"121","author":"Fiorella","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0185","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of LSD-assisted psychotherapy in subjects with anxiety associated with life-threatening diseases: a randomized active placebo-controlled phase 2 pilot study","volume":"202","author":"Gasser","year":"2014","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0190","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0269881114555249","article-title":"LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects","volume":"29","author":"Gasser","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0195","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/schbul\/13.4.643","article-title":"Startle habituation and sensorimotor gating in schizophrenia and related animal models","volume":"13","author":"Geyer","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0200","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.tips.2008.06.006","article-title":"Serotonin research: contributions to understanding psychoses","volume":"29","author":"Geyer","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0205","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0024-3205(98)00262-8","article-title":"Lysergic acid diethylamide (LSD) is a partial agonist of D2 dopaminergic receptors and it potentiates dopamine-mediated prolactin secretion in lactotrophs in vitro","volume":"63","author":"Giacomelli","year":"1998","journal-title":"Life Sci."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0210","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/YIC.0000000000000196","article-title":"Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression","volume":"33","author":"Gobbi","year":"2018","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0215","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","article-title":"Hallucinogens recruit specific cortical 5-HT 2A receptor-mediated signaling pathways to affect behavior","volume":"53","author":"Gonz\u00e1lez-Maeso","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0220","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0924-9338(99)80686-5","article-title":"Hallucinogenic drug induced states resemble acute endogenous psychoses: results of an empirical study","volume":"13","author":"Gouzoulis-Mayfrank","year":"1998","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0225","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0230","series-title":"Psychedelic Drugs Reconsidered","author":"Grinspoon","year":"1979"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0235","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0240","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000467984","article-title":"LSD-assisted psychotherapy in patients with terminal cancer","volume":"8","author":"Grof","year":"1973","journal-title":"Int. Pharmacopsychiatry"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0245","doi-asserted-by":"crossref","first-page":"10150","DOI":"10.1523\/JNEUROSCI.18-23-10150.1998","article-title":"Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors","volume":"18","author":"Haddjeri","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0250","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0376-8716(02)00306-X","article-title":"Hallucinogen persisting perception disorder: what do we know after 50 years?","volume":"69","author":"Halpern","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0255","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/acps.12080","article-title":"Anxiety and depression in psychosis: a systematic review of associations with positive psychotic symptoms","volume":"128","author":"Hartley","year":"2013","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0260","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/0269881114565653","article-title":"Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population","volume":"29","author":"Hendricks","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0265","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/0006-3223(92)90059-9","article-title":"Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research","volume":"32","author":"Hermle","year":"1992","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0270","series-title":"LSD: My Problem Child","author":"Hofmann","year":"2013"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0275","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1073\/pnas.95.2.735","article-title":"5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites","volume":"95","author":"Jakab","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0280","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/sj.mp.4001920","article-title":"Serotonergic vulnerability and depression: assumptions, experimental evidence and implications","volume":"12","author":"Jans","year":"2007","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0285","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/0269881114568039","article-title":"Psychedelics not linked to mental health problems or suicidal behavior: a population study","volume":"29","author":"Johansen","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0290","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s13311-017-0542-y","article-title":"Potential therapeutic effects of psilocybin","volume":"14","author":"Johnson","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0295","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1176\/ajp.153.4.466","article-title":"Serotonin-dopamine interaction and its relevance to schizophrenia","volume":"153","author":"Kapur","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0300","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0305","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/cercor\/bhq237","article-title":"Anxiety dissociates dorsal and ventral medial prefrontal cortex functional connectivity with the amygdala at rest","volume":"21","author":"Kim","year":"2010","journal-title":"Cereb. Cortex"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0310","doi-asserted-by":"crossref","first-page":"10544","DOI":"10.1523\/JNEUROSCI.3007-12.2013","article-title":"Activation of serotonin 2A receptors underlies the psilocybin-induced effects on \u03b1 oscillations, N170 visual-evoked potentials, and visual hallucinations","volume":"33","author":"Kometer","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0315","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.biopsych.2014.04.010","article-title":"Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers","volume":"78","author":"Kraehenmann","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063972","article-title":"Psychedelics and mental health: a population study","volume":"8","author":"Krebs","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0325","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.tips.2017.08.003","article-title":"Psychedelic drugs in biomedicine","volume":"38","author":"Kyzar","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0330","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1038\/sj.npp.1300944","article-title":"Hallucinogen-induced UP states in the brain slice of rat prefrontal cortex: role of glutamate spillover and NR2B-NMDA receptors","volume":"31","author":"Lambe","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0335","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1177\/107906329000300402","article-title":"Substance abuse among sex offenders","volume":"3","author":"Langevin","year":"1990","journal-title":"Ann. Sex Res."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0340","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1176\/ajp.144.9.1239b","article-title":"Relief of obsessive-compulsive symptoms by LSD and psilocin","volume":"144","author":"Leonard","year":"1987","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0345","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0355","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.tips.2005.03.007","article-title":"A renaissance in trace amines inspired by a novel GPCR family","volume":"26","author":"Lindemann","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0360","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0022-3565(25)20792-3","article-title":"LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex","volume":"278","author":"Marek","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0365","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00213-005-2183-9","article-title":"Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis","volume":"180","author":"Marona-Lewicka","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0370","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00213-008-1238-0","article-title":"Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI","volume":"203","author":"Marona-Lewicka","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0375","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/7854_2017_479","article-title":"The effects of hallucinogens on gene expression","volume":"36","author":"Martin","year":"2017","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2014.03.013","article-title":"Chronic LSD alters gene expression profiles in the mPFC relevant to schizophrenia","volume":"83","author":"Martin","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0385","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/brainsci8030047","article-title":"Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives","volume":"8","author":"Martinotti","year":"2018","journal-title":"Brain Sci."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0390","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.neuroimage.2011.05.051","article-title":"Antidepressant medications reduce subcortical\u2013cortical resting-state functional connectivity in healthy volunteers","volume":"57","author":"McCabe","year":"2011","journal-title":"Neuroimage"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0395","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/BF00442251","article-title":"Risperidone (R 64 766), a potent and complete LSD antagonist in drug discrimination by rats","volume":"97","author":"Meert","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0400","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0031-6997(25)06671-2","article-title":"Effects of antipsychotic drugs on serotonin receptors","volume":"43","author":"Meltzer","year":"1991","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0405","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1136\/bmj.331.7509.155","article-title":"Efficacy of antidepressants in adults","volume":"331","author":"Moncrieff","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0410","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.neulet.2012.12.053","article-title":"Chronic treatment with LY341495 decreases 5-HT(2A) receptor binding and hallucinogenic effects of LSD in mice","volume":"536","author":"Moreno","year":"2013","journal-title":"Neurosci. Lett."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0415","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.54","article-title":"Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects","volume":"7","author":"Mueller","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0420","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.brainres.2004.07.044","article-title":"Lysergic acid diethylamide and [\u2212]-2,5-dimethoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex","volume":"1023","author":"Muschamp","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0425","series-title":"Psychosis and Schizophrenia in Adults: Treatment and Management: Updated Edition 2014","article-title":"National institute for health and clinical excellence: guidance","year":"2014"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0430","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0893-133X(01)00405-5","article-title":"A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain","volume":"26","author":"Nichols","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0435","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1471-4159.2004.02515.x","article-title":"Molecular genetic responses to lysergic acid diethylamide include transcriptional activation of MAP kinase phosphatase-1, C\/EBP-\u03b2 and ILAD-1, a novel gene with homology to arrestins","volume":"90","author":"Nichols","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0440","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0169-328X(03)00029-9","article-title":"Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration","volume":"111","author":"Nichols","year":"2003","journal-title":"Mol. Brain Res."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0445","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0026-895X(25)14186-2","article-title":"[3H] WB4101 labels the 5-HT1A serotonin receptor subtype in rat brain. Guanine nucleotide and divalent cation sensitivity","volume":"28","author":"Norman","year":"1985","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0450","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrn3530","article-title":"Effects of schedule I drug laws on neuroscience research and treatment innovation","volume":"14","author":"Nutt","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/bs.pbr.2018.07.008_bb9000","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1590\/1516-4446-2014-1496","article-title":"Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report","volume":"37","author":"Os\u00f3rio","year":"2015","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0455","first-page":"149","article-title":"Psychedelic drugs and mystical experience","volume":"5","author":"Pahnke","year":"1969","journal-title":"Int. Psychiatry Clin."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0460","first-page":"446","article-title":"The experimental use of psychedelic (LSD) psychotherapy","volume":"4","author":"Pahnke","year":"1971","journal-title":"Int. Z. Klin. Pharmakol. Ther. Toxikol. Int. J. Clin. Pharmacol. Ther. Toxicol."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnbeh.2011.00001","article-title":"Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light","volume":"5","author":"Paparelli","year":"2011","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0470","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","article-title":"The pharmacology of lysergic acid diethylamide: a review","volume":"14","author":"Passie","year":"2008","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0475","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0306-4522(97)00268-6","article-title":"Forebrain afferents to the rat dorsal raphe nucleus demonstrated by retrograde and anterograde tracing methods","volume":"82","author":"Peyron","year":"1997","journal-title":"Neuroscience"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0480","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0031-6997(25)06842-5","article-title":"100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug","volume":"47","author":"Popik","year":"1995","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0485","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cub.2016.12.030","article-title":"The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation","volume":"27","author":"Preller","year":"2017","journal-title":"Curr. Biol."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0490","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1523\/JNEUROSCI.1939-17.2018","article-title":"Role of the 5-HT2A receptor in self-and other-initiated social interaction in lysergic acid diethylamide-induced states: a pharmacological fMRI study","volume":"38","author":"Preller","year":"2018","journal-title":"J. Neurosci."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0495","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1176\/appi.ajp.162.6.1171","article-title":"Quality-of-life impairment in depressive and anxiety disorders","volume":"162","author":"Rapaport","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0500","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/0006-8993(86)91090-5","article-title":"Effect of hallucinogens on spontaneous and sensory-evoked locus coeruleus unit activity in the rat: reversal by selective 5-HT2antagonists","volume":"385","author":"Rasmussen","year":"1986","journal-title":"Brain Res."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pnpbp.2017.09.012","article-title":"Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: a systematic review","volume":"81","author":"Reiche","year":"2018","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0510","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00213-005-0068-6","article-title":"The 5-HT 1A receptor and the stimulus effects of LSD in the rat","volume":"182","author":"Reissig","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0515","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/1520-6394(2000)12:1+<2::AID-DA2>3.0.CO;2-4","article-title":"Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders","volume":"12","author":"Ressler","year":"2000","journal-title":"Depress. Anxiety"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0520","doi-asserted-by":"crossref","first-page":"8485","DOI":"10.1073\/pnas.1103029108","article-title":"TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity","volume":"108","author":"Revel","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0525","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.biopsych.2012.05.014","article-title":"Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics","volume":"72","author":"Revel","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0530","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/mp.2012.57","article-title":"A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic-and antidepressant-like activity, improve cognition and control body weight","volume":"18","author":"Revel","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0535","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00213-006-0358-7","article-title":"Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant","volume":"186","author":"Riba","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0540","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/dta.1685","article-title":"Metabolism and urinary disposition of N, N-dimethyltryptamine after oral and smoked administration: a comparative study","volume":"7","author":"Riba","year":"2015","journal-title":"Drug Test. Anal."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0545","first-page":"121","article-title":"LSD-assisted psychotherapy and the human encounter with death","volume":"4","author":"Richards","year":"1972","journal-title":"J. Transpers. Psychol."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0550","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.neuropharm.2015.08.034","article-title":"Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2, 5-dimethoxy-substituted phenethylamines (2C drugs)","volume":"99","author":"Rickli","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0555","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","article-title":"Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens","volume":"26","author":"Rickli","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0560","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.neuropharm.2015.10.016","article-title":"The serotonergic hallucinogen 5-methoxy-N, N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT1A and 5-HT2A receptors","volume":"101","author":"Riga","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0565","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0570","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1177\/0269881116679368","article-title":"Psychedelics in the treatment of unipolar mood disorders: a systematic review","volume":"30","author":"Rucker","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0575","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/JCP.0000000000000436","article-title":"Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study","volume":"36","author":"Sanches","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0580","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jep.2007.04.012","article-title":"Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members","volume":"112","author":"Santos","year":"2007","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0585","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1176\/ajp.108.12.896","article-title":"Lysergic acid diethylamide (LSD-25) a clinical-psychological study","volume":"108","author":"Savage","year":"1952","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0590","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2466\/pr0.1964.14.1.111","article-title":"LSD: therapeutic effects of the psychedelic experience","volume":"14","author":"Savage","year":"1964","journal-title":"Psychol. Rep."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0595","first-page":"241","article-title":"The effects of psychedelic (LSD) therapy on values, personality, and behavior","volume":"2","author":"Savage","year":"1966","journal-title":"Int. J. Neuropsychiatry"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0600","first-page":"59","article-title":"The effectiveness of psychedelic (LSD) therapy: a preliminary report","volume":"2","author":"Savage","year":"1967","journal-title":"Br. J. Soc. Psychiatry"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0605","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/sj.mp.4001682","article-title":"Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics","volume":"10","author":"Seeman","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0610","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0140-6736(12)60600-X","article-title":"Shaping the renaissance of psychedelic research","volume":"380","author":"Sessa","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0615","first-page":"69","article-title":"The psychedelic experience\u2014a new concept in psychotherapy","volume":"4","author":"Sherwood","year":"1962","journal-title":"J. Neuropsychiatr."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0620","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1124\/jpet.115.229765","article-title":"In vitro characterization of psychoactive substances at rat, mouse, and human trace amine-associated receptor 1","volume":"357","author":"Simmler","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0625","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.tacc.2014.03.002","article-title":"Ketamine \u2013 more mechanisms of action than just NMDA blockade","volume":"4","author":"Sleigh","year":"2014","journal-title":"Trends Anaesthesia Crit. Care"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0630","series-title":"LSD: The Consciousness-Expanding Drug","author":"Solomon","year":"1964"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0635","series-title":"DMT: The Spirit Molecule: A doctor's Revolutionary Research into the Biology of near-Death and Mystical Experiences","author":"Strassman","year":"2000"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0640","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1177\/0269881110382466","article-title":"Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies","volume":"25","author":"Studerus","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0645","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0006-8993(01)03121-3","article-title":"Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons","volume":"922","author":"Szabo","year":"2001","journal-title":"Brain Res."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0650","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3389\/fneur.2015.00010","article-title":"Multimodal imaging of dynamic functional connectivity","volume":"6","author":"Tagliazucchi","year":"2015","journal-title":"Front. Neurol."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0655","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.neuron.2005.11.034","article-title":"Mapping cortical activity elicited with electrical microstimulation using FMRI in the macaque","volume":"48","author":"Tolias","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0660","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR* D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/bs.pbr.2018.07.008_bb9005","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/s12888-016-1066-4","article-title":"Euro-DEN Research Group, and Dargan P.I., Psychosis associated with acute recreational drug toxicity: a European case series","volume":"16","author":"Vallersnes","year":"2016","journal-title":"BMC Psychiatry"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0665","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s001270050220","article-title":"Self-reported psychosis-like symptoms and the continuum of psychosis","volume":"34","author":"van Os","year":"1999","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0670","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0006-8993(83)90011-2","article-title":"Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellularly and intracellularly in rat brain slices","volume":"289","author":"Vandermaelen","year":"1983","journal-title":"Brain Res."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0675","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1001\/archpsyc.1983.01790070067008","article-title":"Lsd psychosis or lsd-induced schizophrenia? A multimethod inquiry","volume":"40","author":"Vardy","year":"1983","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0680","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrn2884","article-title":"The neurobiology of psychedelic drugs: implications for the treatment of mood disorders","volume":"11","author":"Vollenweider","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0685","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0893-133X(96)00246-1","article-title":"Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis","volume":"16","author":"Vollenweider","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0690","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0695","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/sj.npp.1301324","article-title":"The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval","volume":"32","author":"Vollenweider","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2016.12.033","article-title":"Crystal structure of an LSD-bound human serotonin receptor","volume":"168","author":"Wacker","year":"2017","journal-title":"Cell"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0705","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.mehy.2008.07.052","article-title":"Endogenous hallucinogens as ligands of the trace amine receptors: a possible role in sensory perception","volume":"72","author":"Wallach","year":"2009","journal-title":"Med. Hypotheses"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0710","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/BF02245940","article-title":"LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors","volume":"118","author":"Watts","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0715","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev-clinpsy-032511-143049","article-title":"Default mode network activity and connectivity in psychopathology","volume":"8","author":"Whitfield-Gabrieli","year":"2012","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0720","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00213-003-1636-2","article-title":"Serotonergic\/glutamatergic interactions: the effects of mGlu2\/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli","volume":"172","author":"Winter","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0725","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1570159X14666160309114549","article-title":"Molecular and cellular mechanisms of rapid-acting antidepressants ketamine and scopolamine","volume":"15","author":"Wohleb","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0730","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1056\/NEJMra012941","article-title":"Post-traumatic stress disorder","volume":"346","author":"Yehuda","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.pbr.2018.07.008_bb0735","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pnpbp.2007.07.009","article-title":"AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes","volume":"32","author":"Zhang","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2018.07.008_bb0740","doi-asserted-by":"crossref","first-page":"265","DOI":"10.31887\/DCNS.2001.3.4\/fxvollenweider","article-title":"Brain mechanisms of hallucinogens and entactogens","volume":"3","author":"Vollenweider","year":"2001","journal-title":"Dialogues Clin. Neurosci."}],"container-title":["Progress in Brain Research","Psychedelic Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079612318300694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079612318300694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T22:00:19Z","timestamp":1758751219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0079612318300694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9780128142554"],"references-count":148,"URL":"https:\/\/doi.org\/10.1016\/bs.pbr.2018.07.008","relation":{},"ISSN":["0079-6123"],"issn-type":[{"value":"0079-6123","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}